APOE and Alzheimer disease: These limitations highlight the value of our findings regarding sleep disturbance assessment, which could complement imaging approaches by providing an accessible clinical marker that may help identify individuals at increased risk for AD-related pathology, particularly among APOE ε4 carriers.